Fig. 3From: Association of CCND1 rs9344 polymorphism with lung cancer susceptibility and clinical outcomes: a case-control studyStratification analyses of CCND1 rs9344 and chemotherapy-induced overall toxicity in lung cancer patients. a–c Additive (a), dominant (b), and recessive (c) models with adjustments of age, sex, stage, histological type, smoking status, and chemotherapy regimens. Each box and horizontal line represent the odds ratio (OR) and 95% confidence interval (CI). NSCLC non-small cell lung carcinoma, ADC adenocarcinoma, SCC squamous cell carcinoma, SCLC small cell lung cancer. Regimen1, platinum + gemcitabine. Regimen2, platinum + etoposide. Regimen3, platinum + pemetrexedBack to article page